Liu Tao,Sheng Qingfeng,Liu Jiangbing,et al.Risk factors related to 3-year EFS in International Neuroblastoma Staging System stage 4 neuroblastoma patients[J].Journal of Clinical Pediatric Surgery,,21():121-127.[doi:10.3760/cma.j.cn.101785-202011036-005]
Click Copy

Risk factors related to 3-year EFS in International Neuroblastoma Staging System stage 4 neuroblastoma patients

References:

[1] Maris JM.Recent advances in neuroblastoma[J].N Engl J Med,2010,362(23):2202-2211.DOI:10.1056/NEJMra0804577.
[2] Ward E,DeSantis C,Robbins A,et al.Childhood and adolescent cancer statistics,2014[J].CA Cancer J Clin,2014,64(2):83-103.DOI:10.3322/caac.21219.
[3] Berthold F,Spix C,Kaatsch P,et al.Incidence,Survival,and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015[J].Pediatr Drugs,2017,19(6):577-593.DOI:10.1007/s40272-017-0251-3.
[4] Park JR,Bagatell R,Cohn SL,et al.Revisions to the international neuroblastoma response criteria:A consensus statement from the national cancer institute clinical trials planning meeting[J].J Clin Oncol,2017,35(22):2580-2587.DOI:10.1200/JCO.2016.72.0177.
[5] Brodeur GM,Pritchard J,Berthold F,et al.Revisions of the international criteria for neuroblastoma diagnosis,staging,and response to treatment[J].J Clin Oncol,1993,11(8):1466-1477.DOI:10.1200/JCO.1993.11.8.1466.
[6] Cohn SL,Pearson ADJ,London WB,et al.The international neuroblastoma risk group (INRG) classification system:An INRG task force report[J].J Clin Oncol,2009,27(2):289-297.DOI:10.1200/JCO.2008.16.6785.
[7] Shimada H,Ambros IM,Dehner LP,et al.Terminology and morphologic criteria of neuroblastic tumors:recommendations by the international neuroblastoma pathology committee[J].Cancer,1999,86(2):349-363.
[8] 朱霞,黄东生,张伟令,等.儿童晚期神经母细胞瘤合并颅内转移14例[J].中华实用儿科临床杂志,2013,28(15):1142-1145.DOI:10.3760/cma.j.issn.2095-428X.2013.15.008. Zhu X,Huang DS,Zhang WL,et al.Advanced neuroblastoma with intracranial metastasis in 14 children[J].Chin J Appl Clin Pediatr,2013,28(15):1142-1145.DOI:10.3760/cma.j.issn.2095-428X.2013.15.008.
[9] Fletcher JI,Ziegler DS,Trahair TN,et al.Too many targets,not enough patients:Rethinking neuroblastoma clinical trials[J].Nat Rev Cancer,2018,18(6):389-400.DOI:10.1038/s41568-018-0003-x.
[10] 陈吉,黄磊,易军.神经母细胞瘤分子治疗研究进展[J].中华小儿外科杂志,2018,39(5):397-400.DOI:10.3760/cma.j.issn.0253-3006.2018.05.016. Chen J,Huang L,Yi J.Research progress in the molecular therapy of neuroblastoma[J].Chin J Pediatr Surg,2018,39(5):397-400.DOI:10.3760/cma.j.issn.0253-3006.2018.05.016.
[11] 姚伟,李凯,郑珊.神经母细胞瘤靶向治疗的应用现状和展望[J].中华小儿外科杂志,2018,39(10):792-796.DOI:10.3760/cma.j.issn.0253-3006.2018.10.017. Yao W,Li K,Zheng S.Applications and prospects of targeted therapy for neuroblastoma[J].Chin J Pediatr Surg,2018,39(10):792-796.DOI:10.3760/cma.j.issn.0253-3006.2018.10.017.
[12] 王婧,李凯.神经母细胞瘤新药研究进展[J].中华小儿外科杂志,2019,40(6):558-562.DOI:10.3760/cma.j.issn.0253-3006.2019.06.017. Wang J,Li K.Recent advances in new drugs for neuroblastoma[J].Chin J Pediatr Surg,2019,40(6):558-562.DOI:10.3760/cma.j.issn.0253-3006.2019.06.017.
[13] 蔡元霞,武志祥,王奕,等.Cdc5l表达对神经母细胞瘤临床及预后评估的意义[J].临床小儿外科杂志,2019,18(6):472-479.DOI:10.3969/j.issn.1671-6353.2019.06.008. Cai YX,Wu ZX,Wang Y,et al.Expression of CDC5L in neuroblastoma and it’s clinical and prognostic significance[J].J Clin Ped Sur,2019,18(6):472-479.DOI:10.3969/j.issn.1671-6353.2019.06.008.
[14] 苏雁,马晓莉,王焕民,等.单中心458例高危神经母细胞瘤患儿临床特征及预后分析[J].中华儿科杂志,2020,58(10):796-801.DOI:10.3760/cma.j.cn112140-20200525-00540. Su Y,Ma XL,Wang H,et al.Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center[J].Chin J Pediatr,2020,58(10):796-801.DOI:10.3760/cma.j.cn112140-20200525-00540.
[15] Samim A,Tytgat GAM,Bleeker G,et al.Nuclear medicine imaging in neuroblastoma:Current status and new developments[J].J Pers Med,2021,11(4):270.DOI:10.3390/jpm11040270.
[16] 汤梦婕,袁晓军,安霞,等.转移性神经母细胞瘤伴骨和骨髓转移的治疗疗效及预后分析[J].中华转移性肿瘤杂志,2019,2(3):18-24.DOI:10.3760/cma.j.issn.2096-5400.2019.03.004. Tang MJ,Yuan XJ,An X,et al.Outcome and prognostic factors of children with bone marrow or bone metastatic neuroblastoma[J].Chin J Metastatic Cancer,2019,2(3):18-24.DOI:10.3760/cma.j.issn.2096-5400.2019.03.004.
[17] Morgenstern DA,London WB,Stephens D,et al.Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma:a study from the International Neuroblastoma Risk Group database[J].Eur J Cancer,2016,65:1-10.DOI:10.1016/j.ejca.2016.06.005.
[18] Saarinen-Pihkala UM,Jahnukainen K,Wikstrom S,et al.Ultrahigh-risk group within the high-risk neuroblastoma category[J].J Pediatr Hematol Oncol,2013,35(6):e254-e259.DOI:10.1097/MPH.0b013e318287326b.
[19] Moreno L,Guo D,Irwin MS,et al.A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma:an international neuroblastoma risk group project[J].Pediatr Blood Cancer,2021,68(3):e28794.DOI:10.1002/pbc.28794.
[20] 郝腾,李斯慧,李兴军,等.伴骨转移神经母细胞瘤患儿的临床特征、治疗效果及预后[J].中华实用儿科临床杂志,2017,32(3):182-186.DOI:10.3760/cma.j.issn.2095-428X.2017.03.005. Hao T,Li SH,Li XJ,et al.Clinical features,treatment and prognosis of neuroblastoma with bone metastasis in children[J].Chin J Appl Clin Pediatr,2017,32(3):182-186.DOI:10.3760/cma.j.issn.2095-428X.2017.03.005.
[21] 张婷,李艳华,李珊珊,等.单中心儿童神经母细胞瘤4期患者临床疗效及预后分析[J].中国小儿血液与肿瘤杂志,2020,25(3):153-158.DOI:10.3969/j.issn.1673-5323.2020.03.007. Zhang T,Li YH,Li SS,et al.Clinical efficacy and prognosis in children with stage ⅳ neuroblastoma:A single-center study[J].J china Pediatr Blood cancer,2020,25(3):153-158.DOI:10.3969/j.issn.1673-5323.2020.03.007.
[22] Morgenstern DA,London WB,Stephens D,et al.Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease:A study from the international neuroblastoma risk group database[J].J Clin Oncol,2014,32(12):1228-1235.DOI:10.1200/JCO.2013.53.6342.
[23] 张广超,王景福.国际神经母细胞瘤危险度分级(inrg)协作组最新共识[J].中国肿瘤临床,2012,39(15):1003-1007.DOI:10.3969/j.issn.1000-8179.2012.15.001. Zhang GC,Wang JF.Latest consensus of International Neuroblastoma Risk Group[J].Chin J Clin Oncol,2012,39(15):1003-1007.DOI:10.3969/j.issn.1000-8179.2012.15.001.
[24] Matthay KK,Shulkin B,Ladenstein R,et al.Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma:A report for the International Neuroblastoma Risk Group (INRG) Task Force[J].Br J Cancer,2010,102(9):1319-1326.DOI:10.1038/sj.bjc.6605621.
[25] Yanik GA,Parisi MT,Shulkin BL,et al.Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma:A report from the Children’s oncology group[J].J Nucl Med,2013,54(4):541-548.DOI:10.2967/jnumed.112.112334.
[26] Decarolis B,Schneider C,Hero B,et al.Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma:Results of the cologne interscore comparison study[J].J Clin Oncol,2013,31(7):944-951.DOI:10.1200/JCO.2012.45.8794.
[27] Marachelian A,Shimada H,Sano H,et al.The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma[J].Pediatr Blood Cancer,2012,58(5):675-681.DOI:10.1002/pbc.23250.

Memo

收稿日期:2020-09-02。
通讯作者:吕志宝,Email:zhibaolyu@163.com

Last Update: 1900-01-01